DHCG Disruptive Dose
Video Interviews With Industry Leaders
The Digital Health Coalition partners with a wide array of pharmaceutical industry leaders and key stakeholders to facilitate and disseminate insights on a range of topics related to digital pharmaceutical marketing innovation.
Disruptive Dose Archive
SVP, Social Center of Excellence, Centered, CMI Media Group
In this DHCG Disruptive Dose, Mark Bard of the DHC Group sits down with Josh Simon, SVP of the Social Center of Excellence at CMI Media Group, to discuss the evolving landscape of social influencers in pharma. They explore the shift from celebrity-driven content to authentic partnerships with HCPs and patients, the challenges of balancing compliance with genuine storytelling, and the differences between consumer, patient, and physician influencers. Josh shares insights on sourcing true digital opinion leaders, the growing role of micro-influencers, and how smaller pharma companies leverage them as a competitive advantage.
CXellence Digital Advisors
In this DHCG Disruptive Dose, Mark Bard of the DHC Group sits down with Andy Kennemer to discuss the state of customer experience (CX) in pharma, highlighting the industry’s reliance on sales reps and the shift toward digital channels post-COVID. They explore the role of AI chatbots in improving engagement and the challenges of scaling human support, measuring CX success, reducing friction, and learning from disruptive brands like Amazon to create seamless patient experiences.
CX/Digital Transformation Leader
In this DHCG Disruptive Dose, Mark Bard of The DHC Group sits down with Rusty Rahmer to discuss pharma’s digital evolution, accelerated post-pandemic. They explore the shift from blockbuster drugs to targeted biopharma and the role of digital in reaching smaller patient populations. Rahmer highlights challenges in executing C-suite transformation goals, accountability gaps among vendors and teams, and the need for integrated marketing, analytics, and technology for real impact.
Head of Digital Innovation & Marketing Operations, Azurity Pharmaceuticals
In this Short Take Mark Bard interviewed Paul Murasko, the current Head of Digital Innovation and Marketing Operations at Azurity. The two discussed what it will mean to be a leader in digital innovation in the pharmaceutical industry in 2025. Murasko emphasized that being a digital pioneer isn’t just about chasing new technologies, but about improving internal processes and getting the basics right before innovating. He also advocated for a test-and-learn culture that rewards both success and failure, rather than setting arbitrary innovation quotas. Paul shared how he plans to apply the concept of “true north” by staying focused on the company’s mission of serving overlooked patients while driving growth through multiple product launches.
Chief Commercial Officer, GoodRx
In this Short Take interview with Mark Bard, Dorothy Gemmell, CCO at GoodRx, highlights the evolution of digital healthcare and the importance of improving patient access and affordability. She identifies four major trends in healthcare: virtual care, care at home, consumerism and e-commerce, and AI-driven hyper-personalization. She shares her perspective on the value of partnerships within the industry towards connecting patients, healthcare providers, and pharmaceutical companies to address affordability challenges. Gemmell expresses optimism about the future of healthcare, citing the convergence of digital infrastructure, AI, and platforms enabling virtual care as drivers for accelerated improvements in healthcare outcomes.
CEO, HealthLink Dimensions
In this Short Take interview, Mark Bard speaks with Amar Duggasani, CEO of HealthLink Dimensions, about current innovations in healthcare data management and the impact of leveraging advanced technology to realize enhancing communication between healthcare organizations and professionals. Duggasani shares insights into the future of healthcare data solutions and the importance of data accuracy in improving patient care.
Check out HealthLink Dimensions’ 2024 NPs and PAs Communications Report HERE
Global Digital Health and Innovation Lead, Sanofi
Mark Bard, with DHC Group, and Nandini Nayar, Global Digital Health and Innovation Lead, Sanofi, discussed the evolution of patient-centricity, patient experience, and overall digital health trends in the pharmaceutical industry. The conversation also discussed challenges in the clinical trial processes and the potential for innovation in patient access for specialty medications. They also explored the potential for pharmaceutical companies to fund the creation of models and care pathways to improve patient diagnosis and control, and the importance of integrating these tools into physicians’ workflows.
Health Experience Officer, Otsuka Precision Health
Mark Bard, DHC Group, and Desiree Priestley, Otsuka Precision Health, discussed Desiree’s experiences on the commercial side of pharma and the challenges and opportunities in the current and future generations of patient support and customer experience programs. They also explored the evolution of patient experience and support in the pharmaceutical industry, the growth of digital therapeutics, and the importance of direct-to-patient (DTP) and customer experience overall.
#GenAI4Pharma